A derivative of eculizumab, from which it differs in 4 amino acid substitutions in complementarity-determining and Fc regions. These changes result in an extended half-life because of enhanced endosomal dissociation of C5 and recycling to the vascular compartment of the antibody through the neonatal Fc receptor. Ravulizumab was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency in 2020 for patients with paroxysmal nocturnal hemoglobinuria (PNH). Learn more here.
Jun
26
2022